We observed a high proportion of clinical recovery in patients with a mild-to-moderate COVID-19 and at high risk of clinical progression following antiviral treatment.

No differences in clinical recovery were observed among nirmatrelvir/ritonavir, molnupiravir, and a short-course of remdesivir.

All three of the antiviral therapies are well tolerated with few adverse events.

Nirmatrelvir/ritonavir was associated with a higher proportion of virological clearance at day 7 after starting the antiviral treatment, compared to molnupiravir and a short course of remdesivir.

Nirmatrelvir/ritonavir was also associated with a shorter time to virological clearance, compared to molnupiravir and a short course of remdesivir.